Session » (0280–0305) Muscle Biology, Myositis & Myopathies – Basic & Clinical Science Poster I

Date: Sunday, October 26, 2025

Time: 10:30AM-12:30PM

Meeting: ACR Convergence 2025

10:30AM-12:30PM: Abstract Number: 0303

A Predictive Model for Liver Enzyme Elevations Based on Creatine Kinase in Idiopathic Inflammatory Myopathies

10:30AM-12:30PM: Abstract Number: 0291

Acute onset inflammatory myositis: Clinical features and survival.

10:30AM-12:30PM: Abstract Number: 0296

Aggregation of HARS1 and internalized antibodies in muscle biopsies of patients with antisynthetase syndrome and anti-Jo1(HARS) autoantibodies

10:30AM-12:30PM: Abstract Number: 0286

Anifrolumab For Treatment Of Refractory Juvenile Dermatomyositis In Adult Patients

10:30AM-12:30PM: Abstract Number: 0281

Anti-IL-6 Autoantibodies and IL-6 Signalling in Idiopathic Inflammatory Myopathies

10:30AM-12:30PM: Abstract Number: 0282

Clinical Meaningfulness and Improvement Thresholds of Myositis Core Set Measures: Association with Patient-Reported Outcomes

10:30AM-12:30PM: Abstract Number: 0294

Clinical relevance of low titer positive myositis-specific autoantibodies and myositis-associated autoantibodies in patients with an underlying malignancy.

10:30AM-12:30PM: Abstract Number: 0290

Comparison of Organ Damage and Survival in Anti-synthetase Syndrome and Other Idiopathic Inflammatory Myopathies: An Analysis of Patients from Turkey

10:30AM-12:30PM: Abstract Number: 0287

Comprehensive Profiling of Neutrophil Subsets Reveals Functional Signatures Linked to Vasculopathic Features in Patients with Inflammatory Myopathies

10:30AM-12:30PM: Abstract Number: 0304

Concordance for myositis-specific autoantibody detection between commercial enzyme-linked immunosorbent assay and line blot assay: a multi-center study across the Asia-Pacific region

10:30AM-12:30PM: Abstract Number: 0285

Delayed-Onset Myopathy in Dermatomyositis: A Retrospective Cohort Study

10:30AM-12:30PM: Abstract Number: 0300

Exploring Malignancy in Anti-synthetase Syndrome: A Multisite Retrospective Study

10:30AM-12:30PM: Abstract Number: 0305

From Movement to Meaning: Exploring Physical Function in IBM with Actigraphy

10:30AM-12:30PM: Abstract Number: 0284

Glucocorticoid Tapering and Relapse Risk in Anti-ARS Antibody-Positive Myositis: A Retrospective Study in a Single-Center Cohort Treated with Immunosuppressants

10:30AM-12:30PM: Abstract Number: 0298

Inter-rater Reliability of Hand-Held Dynamometry in Patients with Idiopathic Inflammatory Myopathy

10:30AM-12:30PM: Abstract Number: 0299

Interpreting Myositis Autoantibody Line-Blot Immunoassays in Real-World Settings: Implications for Diagnostic Accuracy for Inflammatory Myopathies

10:30AM-12:30PM: Abstract Number: 0297

Longitudinal Serum Proteomic Profiles – A Step Closer to Personalized Monitoring in Dermatomyositis

10:30AM-12:30PM: Abstract Number: 0295

Multidimensional Analysis of Fatigue in Idiopathic Inflammatory Myopathies: Clinical, Psychological, and Sociodemographic Determinants

10:30AM-12:30PM: Abstract Number: 0301

Novel HMGCS1 Deficiency Expands Proinflammatory Monocytes and Cytotoxic Populations with Increased Cytokine Release

10:30AM-12:30PM: Abstract Number: 0292

Patterns and Predictors of Longitudinal Trajectories of Pain in Individuals with Inflammatory Myopathies

10:30AM-12:30PM: Abstract Number: 0288

Predictors and Characteristics of Objective Flares in Adult Dermatomyositis

10:30AM-12:30PM: Abstract Number: 0293

Presence of Anti-cN-1A (Mup44, NT5c1A) IgG is Specific for Sporadic Inclusion Body Myositis

10:30AM-12:30PM: Abstract Number: 0280

Sera from dermatomyositis patients induce muscle weakness via activation of type I interferon (IFN) receptors.

10:30AM-12:30PM: Abstract Number: 0289

Standardized Interoperable Data Collection for Myositis Research: Developing Common Data Elements for Myositis Disease Activity Core Set Measures

10:30AM-12:30PM: Abstract Number: 0283

The Performance of Rule-Based Algorithms to Identify Patients With Idiopathic Inflammatory Myopathies in Electronic Health Records

10:30AM-12:30PM: Abstract Number: 0302

Urine Kynurenine Pathway Biomarkers Correlate with Disease Activity and Damage Core Set Measures in JDM

« View all sessions from this meeting

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].